Latest & greatest articles for ondansetron

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on ondansetron or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on ondansetron and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for ondansetron

21. Ondansetron for intravenous use: dose-dependent QT interval prolongation

Ondansetron for intravenous use: dose-dependent QT interval prolongation Ondansetron for intravenous use: dose-dependent QT interval prolongation Drug Safety Update - GOV.UK GOV.UK uses cookies to make the site simpler. Search Ondansetron for intravenous use: dose-dependent QT interval prolongation From: Published: 10 July 2013 Therapeutic area: and New specific guidance on dose-dependent prolongation of QTc with ondansetron. Article date: July 2013 Ondansetron (brand leader Zofran (...) ) is indicated for the prevention and treatment of nausea and vomiting induced by cytotoxic chemotherapy and radiotherapy, and for the prevention and treatment of postoperative nausea and vomiting. Prolongation of QTc interval and cardiac arrhythmia, including Torsade de Pointes, are known risks with ondansetron. In the , we informed you about the results of a study that showed ondansetron causes a dose-dependent prolongation of QTc, and about new recommendations for the maximum single intravenous dose

MHRA Drug Safety Update2013

22. Ondansetron for Pediatric Gastroenteritis

Ondansetron for Pediatric Gastroenteritis Ondansetron for Pediatric Gastroenteritis – TheNNTTheNNT Ondansetron (Zofran) for Pediatric and Adolescent Gastroenteritis 5 for vomiting In Summary, for those who received the ondansetron: Benefits in NNT 80.0% saw no benefit 20.0% were helped by preventing vomiting 100% saw no benefit for avoiding admission 1 in 5 were helped (vomiting stopped) 1 in 6 were helped (IV hydration avoided) None were helped (avoiding admission) Harms in NNT 0% were harmed (...) by medication side effects None were harmed (medication side effect) View As: NNT % Source: Efficacy Endpoints: Cessation of emesis, hospitalization, IV rehydration, readmission to ED within a 72 hour period. Harm Endpoints: Medication side effects [diarrhea] Narrative: Three studies examined administration of weight based oral ondansetron vs a placebo, totaling 465 patients. Included were children under the age of 18 who presented with vomiting and a clinical diagnosis of gastroenteritis. Excluded were

theNNT2012

23. Comparison of Dexamethasone with Ondansetron or Haloperidol for Prevention of Patient-Controlled Analgesia-Related Postoperative Nausea and Vomiting: A Randomized Clinical Trial

Comparison of Dexamethasone with Ondansetron or Haloperidol for Prevention of Patient-Controlled Analgesia-Related Postoperative Nausea and Vomiting: A Randomized Clinical Trial 22297625 2012 04 17 2012 08 23 2013 11 21 1432-2323 36 4 2012 Apr World journal of surgery World J Surg Comparison of dexamethasone with ondansetron or haloperidol for prevention of patient-controlled analgesia-related postoperative nausea and vomiting: a randomized clinical trial. 775-81 10.1007/s00268-012-1446-y (...) Patient-controlled analgesia (PCA) with parenteral opioids is associated with a high incidence of postoperative nausea and vomiting (PONV). The aim of the present study was to compare the efficacy of dexamethasone plus haloperidol with dexamethasone plus ondansetron for the prevention of PCA-related PONV. Patients who received dexamethasone alone were used as controls. A total of 135 female patients (n = 45 in each of three groups) were eligible to participate in this randomized trial. A total of 135

EvidenceUpdates2012

24. Ondansetron (Zofran): important new intravenous dose restriction

Ondansetron (Zofran): important new intravenous dose restriction Ondansetron (Zofran): important new intravenous dose restriction Drug Safety Update - GOV.UK GOV.UK uses cookies to make the site simpler. Search Ondansetron (Zofran): important new intravenous dose restriction From: Published: 20 August 2012 Therapeutic area: and New maximum single intravenous dose of ondansetron for the management of chemotherapy-induced nausea and vomiting (CINV) restricted due to risk of QTc prolongation (...) . Article date: August 2012 Ondansetron is indicated for the prevention and treatment of nausea and vomiting induced by cytotoxic chemotherapy and radiotherapy, and for the prevention and treatment of post-operative nausea and vomiting. In a study in healthy adults, ondansetron 32 mg given intravenously (IV) over 15 minutes caused a maximum mean QTc prolongation of 19.57 (upper 90% confidence interval 21.49) milliseconds. This dose may therefore result in a clinically significant degree of QT

MHRA Drug Safety Update2012

25. Systematic review: Are antiemetics still contraindicated for gastroenteritis in children? Solid evidence now supports the safe use of ondansetron

Systematic review: Are antiemetics still contraindicated for gastroenteritis in children? Solid evidence now supports the safe use of ondansetron Are antiemetics still contraindicated for gastroenteritis in children? Solid evidence now supports the safe use of ondansetron | Evidence-Based Nursing This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in via your Society Log in using your username and password For personal accounts OR managers (...) of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in via your Society Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Are antiemetics still contraindicated for gastroenteritis in children? Solid evidence now supports the safe use of ondansetron Article Text Child health Systematic review Are antiemetics still

Evidence-Based Nursing (Requires free registration)2012

26. Systematic review and meta-analysis: Oral ondansetron decreases vomiting, as well as the need for intravenous fluids and hospital admission, in children with acute gastroenteritis

Systematic review and meta-analysis: Oral ondansetron decreases vomiting, as well as the need for intravenous fluids and hospital admission, in children with acute gastroenteritis Oral ondansetron decreases vomiting, as well as the need for intravenous fluids and hospital admission, in children with acute gastroenteritis | Evidence-Based Medicine This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password For personal (...) accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Oral ondansetron decreases vomiting, as well as the need for intravenous fluids and hospital admission, in children with acute gastroenteritis Article Text Therapeutics Systematic review

Evidence-Based Medicine (Requires free registration)2012

27. Casopitant and ondansetron for postoperative nausea and vomiting prevention in women at high risk for emesis: a phase 3 study

Casopitant and ondansetron for postoperative nausea and vomiting prevention in women at high risk for emesis: a phase 3 study 21339433 2011 02 22 2011 05 10 2013 11 21 1538-3644 146 2 2011 Feb Archives of surgery (Chicago, Ill. : 1960) Arch Surg Casopitant and ondansetron for postoperative nausea and vomiting prevention in women at high risk for emesis: a phase 3 study. 201-6 10.1001/archsurg.2010.327 Postoperative nausea and vomiting (PONV) are associated with a variety of complications (...) ondansetron hydrochloride for the prevention of PONV in the perioperative setting. Forty-three centers in 11 countries. We studied 484 women at high risk for developing PONV scheduled to undergo operations associated with high emetogenic risk. The women were randomized to receive a single dose of intravenous ondansetron, 4 mg, or oral casopitant, 50 mg, in combination with intravenous ondansetron, 4 mg. The primary end point was the proportion of patients who achieved a complete response, defined

EvidenceUpdates2011

28. Antagonistic effects of ondansetron and tramadol? A randomized placebo and active drug controlled study

Antagonistic effects of ondansetron and tramadol? A randomized placebo and active drug controlled study 20488759 2010 12 01 2011 03 21 2013 11 21 1528-8447 11 12 2010 Dec The journal of pain : official journal of the American Pain Society J Pain Antagonistic effects of ondansetron and tramadol? A randomized placebo and active drug controlled study. 1274-81 10.1016/j.jpain.2010.03.003 Opposing effects of ondansetron and tramadol on the serotonin pathway have been suggested which possibly (...) increase tramadol consumption and emesis when co-administered. In a randomized, double-blinded study, 179 patients received intravenous ondansetron, metoclopramide, or placebo for emesis prophylaxis. Analgesic regimen consisted of tramadol intraoperative loading and subsequent patient-controlled analgesia. Tramadol consumption and response to antiemetic treatment were compared. Additionally, plasma concentrations of ondansetron and (+)O-demethyltramadol and CYP2D6 genetic variants were analyzed

EvidenceUpdates2011

29. Emergency department use of oral ondansetron for acute gastroenteritis-related vomiting in infants and children

Emergency department use of oral ondansetron for acute gastroenteritis-related vomiting in infants and children Emergency department use of oral ondansetron for acute gastroenteritis-related vomiting in infants a | Position statements and practice points | Emergency department use of oral ondansetron for acute gastroenteritis-related vomiting in infants a | Canadian Paediatric Society Protecting and promoting the health and well-being of children and youth CPS Member Login | Who We Are What We (...) Do Get Involved Education/CPD Publications Careers > Share PRACTICE POINT Emergency department use of oral ondansetron for acute gastroenteritis-related vomiting in infants and children Posted: Mar 1 2011 Reaffirmed: Feb 1 2016 The Canadian Paediatric Society gives permission to print single copies of this document from our website. For permission to reprint or reproduce multiple copies, please see our . Principal author(s) A Cheng; Canadian Paediatric Society , Paediatr Child Health 2011;16(3

Canadian Paediatric Society2011

30. Zuplenz (ondansetron) oral soluble film

Zuplenz (ondansetron) oral soluble film Drug Approval Package: ZUPLENZ (ondansetron) NDA #022524 Drug Approval Package U.S. Food & Drug Administration Enter Search terms Drug Approval Package - ZUPLENZ (ondansetron) oral soluble film, 4 mg and 8 mg Company: Par Pharmaceutical, Inc. Application No.: 022524 Approval Date: 07/02/2010 Persons with disabilities having problems accessing the PDF files below may call (301) 796-3634 for assistance. (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF

FDA - Drug Approval Package2011

31. Phase II study to evaluate the safety and efficacy of the oral neurokinin-1 receptor antagonist casopitant (GW679769) administered with ondansetron for the prevention of postoperative and postdischarge nausea and vomiting in high-risk patients

Phase II study to evaluate the safety and efficacy of the oral neurokinin-1 receptor antagonist casopitant (GW679769) administered with ondansetron for the prevention of postoperative and postdischarge nausea and vomiting in high-risk patients 20526194 2010 06 25 2010 07 22 2013 11 21 1528-1175 113 1 2010 Jul Anesthesiology Anesthesiology Phase II study to evaluate the safety and efficacy of the oral neurokinin-1 receptor antagonist casopitant (GW679769) administered with ondansetron (...) for the prevention of postoperative and postdischarge nausea and vomiting in high-risk patients. 74-82 10.1097/ALN.0b013e3181d7b13a In recent years, there has been an increased interest in using a multimodal approach with combined agents to treat postoperative nausea and vomiting. This study evaluated whether the addition of an oral dose of the neurokinin-1 receptor antagonist casopitant improved the antiemetic efficacy of an intravenous dose of ondansetron hydrochloride. The authors enrolled 702 premenopausal

EvidenceUpdates2010

32. Ondansetron in childhood gastroenteritis

Ondansetron in childhood gastroenteritis BestBets: Ondansetron in childhood gastroenteritis Ondansetron in childhood gastroenteritis Report By: Dr Helen Rumbold - ST3 Emergency Medicine Search checked by Dr Jude Reay - Locum Consultant Institution: Poole General Hospital Date Submitted: 24th June 2007 Date Completed: 22nd April 2010 Last Modified: 29th April 2010 Status: Green (complete) Three Part Question In [children with vomiting due to viral gastroenteritis] does [ondansetron] reduce (...) the requirement for [IV rehydration] Clinical Scenario A 3 year old child presents to the emergency department with a twenty four hour history of vomiting, diarrhoea and reduced oral intake. You wonder whether giving oral ondansetron would improve the success of oral rehydration and reduce the requirement for IV rehydration. Search Strategy Medline via Ovid interface 1950 � week 3 November 2009 and the Cochrane library issue 4 2008 [{(ondansetron.mp. or exp Ondansetron or zofran.mp.) AND (exp Gastroenteritis

BestBETS2010

33. Oral ondansetron administration in emergency departments to children with gastroenteritis: an economic analysis

Oral ondansetron administration in emergency departments to children with gastroenteritis: an economic analysis Oral ondansetron administration in emergency departments to children with gastroenteritis: an economic analysis Oral ondansetron administration in emergency departments to children with gastroenteritis: an economic analysis Freedman SB, Steiner MJ, Chan KJ Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each (...) abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary This study evaluated the cost-effectiveness of oral ondansetron for children with vomiting, secondary to gastroenteritis, in the emergency department. The authors concluded that ondansetron plus oral rehydration therapy was dominant, as it was less costly and more beneficial than oral rehydration alone. Small

NHS Economic Evaluation Database.2010

34. A randomized controlled trial of pentazocine versus ondansetron for the treatment of intrathecal morphine-induced pruritus in patients undergoing cesarean delivery

A randomized controlled trial of pentazocine versus ondansetron for the treatment of intrathecal morphine-induced pruritus in patients undergoing cesarean delivery 19843798 2009 10 21 2009 11 05 2013 11 21 1526-7598 109 5 2009 Nov Anesthesia and analgesia Anesth. Analg. A randomized controlled trial of pentazocine versus ondansetron for the treatment of intrathecal morphine-induced pruritus in patients undergoing cesarean delivery. 1606-11 10.1213/ANE.0b013e3181b72e93 Ondansetron is effective (...) for the treatment of intrathecal morphine-induced pruritus. There is evidence that kappa-opioid receptor agonists have antipruritic activity. Pentazocine is an agonist of kappa-opioid receptors and partial agonist at mu-opioid receptors. We therefore performed a randomized, double-blind trial to compare the efficacy of pentazocine and ondansetron for the treatment of pruritus associated with intrathecal injection of morphine in patients undergoing cesarean delivery. Two hundred eight parturients who developed

EvidenceUpdates2010

35. Ondansetron reduced the need for intravenous hydration in children with acute gastritis/gastroenteritis and dehydration

Ondansetron reduced the need for intravenous hydration in children with acute gastritis/gastroenteritis and dehydration Ondansetron reduced the need for intravenous hydration in children with acute gastritis/gastroenteritis and dehydration | Evidence-Based Medicine This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name (...) or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Ondansetron reduced the need for intravenous hydration in children with acute gastritis/gastroenteritis and dehydration Article Text Therapeutics Ondansetron reduced the need for intravenous hydration in children with acute gastritis/gastroenteritis and dehydration Statistics

Evidence-Based Medicine (Requires free registration)2009

36. Haloperidol versus ondansetron for prophylaxis of postoperative nausea and vomiting

Haloperidol versus ondansetron for prophylaxis of postoperative nausea and vomiting 18420852 2008 04 18 2008 05 01 2014 11 20 1526-7598 106 5 2008 May Anesthesia and analgesia Anesth. Analg. Haloperidol versus ondansetron for prophylaxis of postoperative nausea and vomiting. 1407-9, table of contents 10.1213/ane.0b013e3181609022 Haloperidol is effective for postoperative nausea and vomiting prophylaxis, but there are almost no data comparing it to 5-HT(3) antagonists. Two hundred forty-four (...) adults were randomized to receive i.v. haloperidol 1 mg or ondansetron 4 mg, during general anesthesia. Nausea, vomiting, need for rescue, sedation, extrapyramidal effects, QTc intervals, and time to postanesthesia care unit discharge were evaluated with a third-party blind design. There was no intergroup difference in any measure of efficacy or toxicity. Haloperidol and ondansetron subjects (78.2% and 76.8%) had complete response. Postoperatively, prolonged QTc occurred in 28.9% and 22.1% (N.S

EvidenceUpdates2008

37. Haloperidol plus ondansetron versus ondansetron alone for prophylaxis of postoperative nausea and vomiting

Haloperidol plus ondansetron versus ondansetron alone for prophylaxis of postoperative nausea and vomiting 18420853 2008 04 18 2008 05 01 2014 11 20 1526-7598 106 5 2008 May Anesthesia and analgesia Anesth. Analg. Haloperidol plus ondansetron versus ondansetron alone for prophylaxis of postoperative nausea and vomiting. 1410-3, table of contents 10.1213/ane.0b013e31816091f0 Haloperidol 1 mg and ondansetron 4 mg are equally safe and effective for postoperative nausea and vomiting prophylaxis. We (...) compared the combination to ondansetron alone in a mixed surgical population. Two-hundred and sixty-eight adults undergoing general anesthesia received 4 mg ondansetron plus 1 mg haloperidol or saline in this randomized, double-blind protocol. Efficacy and safety data were obtained until 480 min after postanesthesia care unit entry. The combination had more complete responders (76.2% vs 59.2%), less nausea, less rescue, and longer time to rescue. Sedation, time to postanesthesia care unit discharge

EvidenceUpdates2008

38. Ondansetron versus promethazine to treat acute undifferentiated nausea in the emergency department: a randomized, double-blind, noninferiority trial

Ondansetron versus promethazine to treat acute undifferentiated nausea in the emergency department: a randomized, double-blind, noninferiority trial 18304050 2008 02 28 2008 07 21 2013 11 21 1553-2712 15 3 2008 Mar Academic emergency medicine : official journal of the Society for Academic Emergency Medicine Acad Emerg Med Ondansetron versus promethazine to treat acute undifferentiated nausea in the emergency department: a randomized, double-blind, noninferiority trial. 209-15 10.1111/j.1553 (...) -2712.2008.00060.x The authors sought to compare ondansetron and promethazine among emergency department (ED) patients with undifferentiated nausea. The hypothesis was that ondansetron was not inferior to promethazine and that rates of adverse effects were similar. This was a randomized double-blind noninferiority clinical trial conducted in an urban academic ED. A convenience sample of nonpregnant adults with at least 40 mm of self-reported nausea measured on a 100-mm visual analog scale (VAS) were enrolled

EvidenceUpdates2008

39. Meta-analysis: ondansetron for vomiting in acute gastroenteritis in children

Meta-analysis: ondansetron for vomiting in acute gastroenteritis in children Meta-analysis: ondansetron for vomiting in acute gastroenteritis in children Meta-analysis: ondansetron for vomiting in acute gastroenteritis in children Szajewska H, Gieruszczak-Bialek D, Dylag M CRD summary This review concluded that there is insufficient evidence to recommend the routine use of ondansetron for vomiting during acute gastroenteritis in children, despite some clinical benefits. There were considerable (...) limitations to this review but, overall, the authors' conclusion appears reasonable and the recommendations for future research seem justified. Authors' objectives To determine the effects of ondansetron for the treatment of vomiting during acute gastroenteritis in children. Searching MEDLINE (1966 to August 2006), EMBASE (1980 to August 2006), CINAHL (1982 to August 2006), the Cochrane Database of Systematic Reviews (Issue 3, 2006) and the Cochrane Controlled Trials Register (Issue 3, 2006) were searched

DARE.2007

40. Oral ondansetron for gastroenteritis in a pediatric emergency department.

Oral ondansetron for gastroenteritis in a pediatric emergency department. 16625009 2006 04 20 2006 04 26 2013 11 21 1533-4406 354 16 2006 Apr 20 The New England journal of medicine N. Engl. J. Med. Oral ondansetron for gastroenteritis in a pediatric emergency department. 1698-705 Vomiting limits the success of oral rehydration in children with gastroenteritis. We conducted a double-blind trial to determine whether a single oral dose of ondansetron, an antiemetic, would improve outcomes (...) in children with gastroenteritis. We enrolled 215 children 6 months through 10 years of age who were treated in a pediatric emergency department for gastroenteritis and dehydration. After being randomly assigned to treatment with orally disintegrating ondansetron tablets or placebo, the children received oral-rehydration therapy according to a standardized protocol. The primary outcome was the proportion who vomited while receiving oral rehydration. The secondary outcomes were the number of episodes

NEJM2006